Schedule 13D ownership disclosure

Jade Biosciences Inc

Common Stock, $0.0001 par value · CUSIP: 008064206

Event date: 2025-04-28

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Fairmount Funds Management LLCReported CIK 0001802528

    Shares: 7,249,356 · Class: 19.99%

  • Fairmount Healthcare Fund II L.P.Reported CIK 0001769651

    Shares: 4,592,551 · Class: 12.66%

  • Fairmount Healthcare Co-Invest IV L.P.Reported CIK 0002042283

    Shares: 2,655,817 · Class: 8.24%

  • Peter Evan HarwinReported CIK 0001663607

    Shares: 7,249,356 · Class: 19.99%

  • Tomas KiselakReported CIK 0001830177

    Shares: 7,249,356 · Class: 19.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-062146
Form type
SCHEDULE 13D
Filer
Fairmount Funds Management LLC
CIK
CIK 1802528
Filed
May 01, 2025
Reporting period
Apr 28, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub